News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
257,849 Results
Type
Article (13887)
Company Profile (257)
Press Release (243705)
Section
Business (79537)
Career Advice (163)
Deals (13221)
Drug Delivery (28)
Drug Development (50351)
Employer Resources (34)
FDA (5666)
Job Trends (5138)
News (144251)
Policy (10120)
Tag
Academia (916)
Africa (146)
Allergies (30)
Alliances (21482)
Alzheimer's disease (683)
Antibody-drug conjugate (ADC) (31)
Approvals (5629)
Arizona (38)
Artificial intelligence (30)
Asia (16700)
Australia (2809)
Bankruptcy (97)
Best Places to Work (4371)
Biotechnology (215)
C2C Services and Suppliers (10797)
California (1182)
Canada (483)
Cancer (279)
Career advice (141)
CAR-T (33)
Cell therapy (93)
China (88)
Clinical research (39121)
Collaboration (82)
Colorado (35)
Compensation (37)
Connecticut (39)
COVID-19 (1034)
Cystic fibrosis (58)
Data (200)
Diabetes (38)
Diagnostics (1165)
Earnings (28489)
Employer resources (31)
Europe (35798)
Events (46020)
Executive appointments (92)
FDA (5767)
Florida (120)
Funding (93)
Gene editing (27)
Gene therapy (77)
GLP-1 (260)
Government (1081)
Healthcare (6607)
Hotbed/Location (185284)
Illinois (72)
Indiana (43)
Infectious disease (1043)
Inflammatory bowel disease (78)
IPO (7170)
Job creations (861)
Job search strategy (136)
Kansas (52)
Layoffs (178)
Legal (1389)
Lung cancer (68)
Maryland (181)
Massachusetts (963)
Medical device (2563)
Medtech (2564)
Mergers & acquisitions (6045)
Metabolic disorders (127)
Michigan (38)
Minnesota (66)
Neuroscience (785)
New Jersey (319)
New York (381)
NextGen Class of 2024 (2015)
Non-profit (881)
North Carolina (324)
Northern California (520)
Obesity (72)
Ohio (62)
Opinion (91)
Parkinson's disease (31)
Patents (36)
Peanut (27)
Pennsylvania (270)
People (24797)
Pharmaceutical (41)
Phase I (13718)
Phase II (18204)
Phase III (11588)
Pipeline (69)
Postmarket research (842)
Preclinical (5776)
Press Release (30)
Rare diseases (101)
Real estate (1426)
Regulatory (8071)
Research institute (935)
South America (215)
Southern California (490)
Startups (1967)
Texas (109)
United States (4546)
Vaccines (133)
Washington State (150)
Weight loss (56)
Date
Today (111)
Last 7 days (403)
Last 30 days (1258)
Last 365 days (21560)
2024 (14923)
2023 (22488)
2022 (26936)
2021 (28031)
2020 (23715)
2019 (16377)
2018 (11891)
2017 (13838)
2016 (11921)
2015 (14412)
2014 (10455)
2013 (7522)
2012 (7565)
2011 (7644)
2010 (7456)
257,849 Results for "storm therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Beach
First Patient in STORM-PE RCT Enrolled Evaluating Penumbra’s Latest Computer Assisted Vacuum Thrombectomy - Lightning Flash™ - for Treatment of Acute Pulmonary Embolism
Penumbra, Inc. announced the first patient enrolled in STORM-PE, a first-of-its-kind prospective, multi-center, randomized controlled trial evaluating anticoagulation alone vs anticoagulation plus Lightning Flash™ for the treatment of pulmonary embolism (PE).
November 28, 2023
·
6 min read
Drug Development
Trefoil Therapeutics’ Lead Investigational Candidate TTHX1114 Improves Rate of Visual Recovery after Descemet Stripping Only (DSO) in Phase 2 STORM Data Presented at ASCRS Annual Meeting
Trefoil Therapeutics today announced that TTHX1114 was found to improve the rate of visual recovery and corneal deturgescence (state of relative dehydration maintained by the normal cornea that is necessary for transparency) after Descemet Stripping Only (DSO) in a dose-responsive manner in the Phase 2 STORM study.
May 8, 2023
·
5 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Pharm Country
BrainStorm Cell Therapeutics to Provide Corporate Mid-Year Update on NurOwn Program
BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced that it will hold a mid-year corporate update to discuss recent positive developments in the NurOwn® program on Monday, July 8, at 8:00 a.m. U.S. Eastern Time.
July 1, 2024
·
4 min read
Business
BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer
BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced the appointment of Hartoun Hartounian Ph.D. as its new EVP and COO, effective as of June 18, 2024.
June 20, 2024
·
6 min read
Pharm Country
BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering
BrainStorm Cell Therapeutics Inc announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 11,111,111 shares of the Company’s common stock at a purchase price of $0.36 per share in a registered direct offering.
June 27, 2024
·
5 min read
Drug Development
BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn® Clinical Trial
BrainStorm Cell Therapeutics Inc. ment with the U.S. Food and Drug Administration (FDA) on the Chemistry, Manufacturing, and Controls (CMC) aspects of Brainstorm’s Phase 3b clinical trial for NurOwn.
June 26, 2024
·
4 min read
Policy
FDA Provides Update Regarding Storm Damage at Pfizer Facility in North Carolina
The U.S. Food and Drug Administration is working closely with Pfizer to assess the impact of the damage at Pfizer’s Rocky Mount, North Carolina, facility.
July 21, 2023
·
3 min read
Business
BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the First Quarter ended March 31, 2024 and provided a corporate update.
May 14, 2024
·
10 min read
Pharm Country
BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From Longer-Term Treatment with NurOwn
BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell therapeutics for neurodegenerative diseases, will present new biomarker data suggesting that ALS patients may benefit from longer-term treatment with debamestrocel.
May 20, 2024
·
8 min read
1 of 25,785
Next
